Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
Anglicheau
D
D
Service de Néphrologie et de Transplantation Rénale, Hôpital Saint Louis, Paris, France.
Lautrette
A
A
Scieux
C
C
Thervet
E
E
Martinez
F
F
Flamant
M
M
Morinet
F
F
Legendre
C
C
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D011355:Prodrugs / Q000627:therapeutic use; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000956:Antigens, Viral; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D011355:Prodrugs; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir